FROM API CAPITAL TO VACCINE POWERHOUSE How Hyderabad built a life-sciences ecosystem

 

BIZ MASALA  |  FORENSIC BUSINESS & ECONOMICS

A life-sciences team in a facility branded Bharat Biotech, in a photograph supplied for this story. The exact date and facility context have not been independently verified; image rights should be cleared before publication.

FROM API CAPITAL TO VACCINE POWERHOUSE

How Hyderabad built a life-sciences ecosystem—and the early triad that helped change its trajectory

By Murthy ASR  |  Biz Masala

The bigger story is not just vaccines

Hyderabad’s life-sciences story is often told through a striking modern claim: Telangana accounts for about one-third of global vaccine production. The state’s 2026–30 Life Sciences Policy repeats that figure and describes an ecosystem of more than 2,000 life-sciences companies, while identifying Genome Valley as a major research and manufacturing cluster. These are official state figures and should be read as such: production capacity and output are not identical, and the global share depends on the definition and denominator used. [1]

The more revealing question is how a city with a strong base in bulk drugs and generic pharmaceuticals built the capabilities to develop, validate, manufacture and supply complex biological products. This was not a single leap, nor the work of one company. It required scientists, entrepreneurs willing to risk capital, shared research infrastructure, government support, manufacturing discipline, regulatory systems and access to global procurement.

Milestones in Hyderabad’s biotech ecosystem. Dates are drawn from official institutional and company histories; the sequence alone does not prove causation.

Stage 1: The API and generic-drug base

Before the biotechnology cluster became prominent, Hyderabad had already accumulated pharmaceutical capabilities around bulk drugs, active pharmaceutical ingredients (APIs), formulations and process chemistry. Industrial areas such as Jeedimetla, Nacharam, Balanagar and Patancheru formed part of this base. The presence of IDPL and the growth of private pharmaceutical firms helped create a pool of technical workers, production experience, suppliers and industrial infrastructure. [2]

It would be too simple to describe this earlier industry as merely reverse engineering. Generic-drug manufacturing can require sophisticated chemistry, process optimisation, quality control and regulatory compliance. But biological products introduced a different set of challenges: living systems, cell culture, fermentation, purification, cold-chain requirements, and demanding consistency and safety controls.

Stage 2: Shantha Biotechnics and the recombinant breakthrough

Shantha Biotechnics, founded in Hyderabad in 1993 by K. I. Varaprasad Reddy and colleagues, became a landmark in India’s move into recombinant biotechnology. Its hepatitis-B vaccine, Shanvac-B, was launched in August 1997. India’s Technology Development Board records that the project was supported through a commercialisation loan and describes the vaccine as an import substitute and a cost-effective product. [3]

The price story is powerful, but it needs careful sourcing. IKP’s retrospective account says Shanvac-B was produced at less than US$1 a dose when comparable global supply was being sold at about US$23. That is a historical comparison cited by the institution, not a current price or a universal Indian retail price. We therefore do not construct an apparently precise price series from ₹800 to ₹150 to below ₹20 without consistent, date-specific evidence. [4]

The significance was larger than a price point. Shantha demonstrated that a Hyderabad company could develop and commercialise a recombinant human vaccine rather than rely exclusively on small-molecule medicines. In July 2009, Sanofi-aventis and Mérieux Alliance announced an agreement under which Sanofi Pasteur would acquire control of Shantha through Mérieux Alliance’s subsidiary. The transaction linked an Indian vaccine innovator to a global vaccines group and international manufacturing and distribution networks. [5]

The acquisition should not be framed as either a simple triumph or a loss of Indian innovation. It illustrates the trade-off between the capital, scale and global access available through multinational ownership and the question of where intellectual property, decision-making and future research capabilities ultimately reside.

Stage 3: Bharat Biotech and the ambition to invent

Bharat Biotech was established in Hyderabad in 1996 by Krishna Ella and Suchitra Ella. Its company history describes the founders’ ambition to develop affordable vaccines and biotherapeutics from India. The company’s product milestones include Revac-B, the rotavirus vaccine Rotavac, and Typbar-TCV, a typhoid conjugate vaccine. [6]

WHO’s prequalification database lists Rotavac and Typbar-TCV as products manufactured by Bharat Biotech, with prequalification dates of January 2018 and December 2017 respectively. WHO prequalification is significant because it can enable procurement by United Nations agencies and other international buyers; it is not, by itself, a statement that a product is the best in every clinical or commercial dimension. [7]

Bharat Biotech’s story also illustrates why vaccine innovation is different from simply producing a molecule. Product development must be followed by clinical trials, regulatory review, manufacturing validation, quality systems, cold-chain planning and sustained supply. The public-health value of an innovation depends on whether it can be produced reliably, approved appropriately, procured at scale and delivered where it is needed.

Stage 4: IKP Knowledge Park—the missing infrastructure layer

A research scientist with a promising idea needs more than an office and an internet connection. Biotechnology requires specialised laboratories, analytical instruments, technical support, biosafety systems and a path from early experiments to product development. Shared facilities can reduce the initial capital burden for start-ups and research teams.

IKP Knowledge Park’s own history dates its incorporation to 24 July 1998 and the inauguration of its 200-acre Genome Valley campus to 28 October 1999. It was promoted by ICICI and developed with support from the then Government of Andhra Pradesh. Its timeline records Medicorp Technologies as the first company at the park in 2000 and Deepanwita Chattopadhyay’s appointment as CEO in 2001. [8]

This institutional layer is easy to overlook because it does not produce a vaccine with a recognisable brand name. Yet shared infrastructure can help bridge a difficult gap between university research and a commercially viable, quality-controlled product. IKP’s role should not be overstated as the sole incubator of Genome Valley, but its early presence helped establish a model of purpose-built life-sciences infrastructure.

The ecosystem in pictures

The IKP Knowledge Park sign, supplied photograph. The image identifies the institution; it does not independently establish the date or circumstances of the photograph.

A modern research-campus exterior, supplied photograph. The precise facility and location have not been independently confirmed.

A team photographed in a Bharat Biotech-branded facility, supplied photograph. Verify date, location, identities and usage rights before publication.

A portrait supplied with the story’s image set. The individual’s identity should be confirmed against an authoritative company source before a named caption is published.

A speaker photographed at an event, supplied image. The individual and event context should be verified before publication.

A portrait supplied for the story; verify identity and image rights before assigning a name.

The institutional chain: from research to global supply

The story is best understood as a chain of complementary capabilities. Universities and research institutes contribute scientific knowledge and trained people. Entrepreneurs translate ideas into product candidates. Parks and incubators provide shared facilities and networks. Public programmes and private investors absorb different kinds of early risk. Manufacturers scale production under quality systems. Regulators assess safety, quality and efficacy; WHO prequalification can support access to international procurement. Public buyers, donors and national immunisation programmes create demand.

Conceptual framework. It maps functions, not a quantified attribution of Genome Valley’s success to individual institutions.

Genome Valley today: scale, but what kind of value?

The Telangana government’s current policy describes Genome Valley as India’s first organised life-sciences cluster and says it hosts more than 250 organisations, with major vaccine manufacturers and WHO-prequalified products for global supply. The same policy describes Telangana as having installed vaccine manufacturing capacity of approximately 14 billion doses. These are official government claims and are useful measures of ambition and industrial scale; they should not be mistaken for audited annual output or for a measure of how much research value remains locally. [1]

The next stage is a shift from volume to value: biologics, biosimilars, advanced biomanufacturing, clinical research, medical devices, precision medicine and global capability centres. Telangana’s 2026–30 policy explicitly identifies several of these areas. The opportunity is to build not just capacity to manufacture products developed elsewhere, but a larger base of intellectual property, discovery research, clinical development and globally competitive home-grown firms. [1]

That transition is difficult. Discovery is uncertain and expensive; clinical development can fail; biologics manufacturing is capital intensive; and global procurement is competitive. A cluster’s success therefore cannot be measured by company count alone. It should also be assessed through R&D spending, patents that translate into products, clinical-trial activity, product approvals, export value, skilled employment, local supplier depth and the share of value retained in the region.

Comparative evolution matrix

Dimension	Pharma base	Biotech and life sciences expansion
Core capability	APIs, bulk drugs, formulations, process chemistry	Recombinant vaccines, biologics, cell culture, advanced manufacturing
Infrastructure	Industrial estates, production facilities, technical workforce	IKP science park, Genome Valley, shared labs and research infrastructure
Representative anchors	IDPL and private pharmaceutical manufacturers	Shantha Biotechnics, Bharat Biotech, Biological E. and other cluster firms
Route to market	Domestic and export generic-drug markets	National immunisation programmes, regulated markets and international procurement
Strategic challenge	Quality, environmental compliance, price competition	R&D risk, clinical validation, scale-up, intellectual property and global access

What this history does—and does not—prove

The evidence supports a story of cumulative institution-building: a pre-existing pharmaceutical base; Shantha’s 1997 recombinant hepatitis-B vaccine; Bharat Biotech’s subsequent vaccine-development programme; IKP’s purpose-built science park; and Genome Valley’s growth into a major life-sciences cluster. It also supports the importance of public policy, private risk-taking, shared infrastructure and international quality systems.

It does not prove that the three organisations alone created Genome Valley, that every company in the cluster grew because of them, or that all the headline claims about vaccine share use identical definitions. Nor should the term ‘one-third of global vaccine production’ be read as one-third of global vaccine revenue, R&D or every vaccine type. The state’s policy uses it as a manufacturing-capacity/output claim; the precise metric should be clarified whenever possible.

A deeper follow-up would examine the public and private capital behind the cluster, the number of locally developed products that reached international procurement, the ownership of resulting intellectual property, and the distribution of skilled jobs and supplier opportunities.

Conclusion: Hyderabad’s next leap

Hyderabad’s evolution from a strong API and generic-drug base into a global vaccine manufacturing centre was not a miracle and not a single-company story. It was the result of capabilities accumulating across firms, laboratories, infrastructure, government policy, scientific talent and global health markets. Shantha showed that recombinant vaccine development could be commercialised locally; Bharat Biotech built a continuing product-development story; IKP helped create the specialised infrastructure that early life-sciences ventures needed; and Genome Valley provided a physical and institutional home for the wider cluster.

The next question is whether the ecosystem can move further up the value chain. Manufacturing billions of doses matters enormously to global health. But a truly innovation-led life-sciences capital will also generate more original discoveries, clinical evidence, intellectual property and globally competitive products whose value is created—not merely manufactured—in Hyderabad.

Sources and verification notes

·       [1] Government of Telangana / Invest Telangana, Next-Gen Life Sciences Policy 2026–2030. State-reported figures on companies, vaccine capacity and Genome Valley; interpret as official policy claims. https://invest.telangana.gov.in/policy-life-sciences/

·       [2] Government of Telangana, Life Sciences Policy and industrial-history material on Hyderabad’s pharmaceutical base and Genome Valley. https://startup.telangana.gov.in/wp-content/uploads/2021/06/Life-Sciences-Policy.pdf

·       [3] Technology Development Board, Government of India, Hepatitis-B Vaccination / Shanvac-B history. https://www.tdb.gov.in/hepatitis-b-vaccination

·       [4] IKP Knowledge Park, “Twenty Prolific Years of Life Sciences Startup Ecosystem,” retrospective by Deepanwita Chattopadhyay; price comparison attributed to IKP’s account. https://ikpknowledgepark.com/wp-content/uploads/2024/06/twenty-prolific-years-of-life-sciences-DC-BioSpectrum.pdf

·       [5] Sanofi-aventis and Mérieux Alliance announcement, 27 July 2009, acquisition of control of Shantha Biotechnics through ShanH. https://www.sec.gov/Archives/edgar/data/1121404/000119312509158110/dex992.htm

·       [6] Bharat Biotech, company history and milestones. https://ftp.bharatbiotech.com/history_milestones.html

·       [7] WHO Prequalification of Medical Products: Rotavac and Typbar-TCV product pages. https://extranet.who.int/prequal/vaccines/p/rotavac-0 ; https://extranet.who.int/prequal/vaccines/p/typbar-tcv

·       [8] IKP Knowledge Park, official history and milestones; 1998 incorporation and 1999 park inauguration. https://ikpevents.com/ikp/

Publication note

The hero is a real photograph supplied in this conversation, not artwork. The timeline and process-chain graphics are original explanatory visuals inside the article. Supplied photographs are not automatically copyright-cleared; confirm provenance, identity, context and publication rights before release. Captions deliberately avoid naming people or facilities where identity/location has not been independently verified.

BIZ MASALA  |  Murthy ASR